EC
SWTX

EcoR1 Capital’s SpringWorks Therapeutics SWTX Stock Holding History

EcoR1 Capital’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,560,000
Closed -$56.4M – 61
2024
Q4 		$56.4M Buy
+1,560,000
New +$54.5M 2.13% 13
2023
Q4 		– Sell
-3,460,208
Closed -$80M – 59
2023
Q3 		$80M Hold
3,460,208
– – 2.7% 12
2023
Q2 		$90.7M Hold
3,460,208
– – 2.22% 14
2023
Q1 		$89.1M Hold
3,460,208
– – 2.87% 12
2022
Q4 		$90M Hold
3,460,208
– – 2.74% 11
2022
Q3 		$98.7M Buy
+3,460,208
New +$99.2M 2.91% 9
2022
Q2 		– Sell
-325,881
Closed -$18.4M – 95
2022
Q1 		$18.4M Buy
+325,881
New +$18.6M 0.58% 33

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

EcoR1 Capital's SWTX Position: Q1 2025 in Review

EcoR1 Capital sold out of SpringWorks Therapeutics (SWTX) in Q1 2025, closing a stake of 1,560,000 shares — an estimated $56.4M sold.

EcoR1 Capital first reported a position in SWTX in Q1 2022 and held it in 7 quarters. The position peaked at $98.7M in Q3 2022. 306 funds tracked by Wall St. Rank hold SWTX as of Q1 2025.

  • EcoR1 Capital reported no remaining SpringWorks Therapeutics position as of Q1 2025 after selling out during the quarter.
  • EcoR1 Capital sold 1,560,000 SpringWorks Therapeutics shares in Q1 2025, an estimated $56.4M.
  • EcoR1 Capital first reported a position in SpringWorks Therapeutics in Q1 2022 and held it in 7 quarters.
  • EcoR1 Capital's SpringWorks Therapeutics position peaked at $98.7M in Q3 2022.
  • 306 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2025.

Based on EcoR1 Capital's 13F filing for Q1 2025, filed 15 May 2025.